A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | December 2000 |
| End Date: | March 2006 |
A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab
This study will compare kidney function in kidney transplant patients following treatment
with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).
The anticipated time on study treatment is 6-12 months, and the target sample size is 500+
individuals.
with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).
The anticipated time on study treatment is 6-12 months, and the target sample size is 500+
individuals.
Inclusion Criteria:
- adult patients greater than 18 years of age
- recipients of primary kidney transplant
- single-organ recipients (kidney only)
Exclusion Criteria:
- previous treatment with Zenapax
- history of malignancy (except localized skin cancer)
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials